1st Quarter - Report

TARPLIN STRATEGIES LLC for GENENTECH, INC.

Firm
Client
Income
$75,000
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - taxes and fees assessed on the pharmaceutical industry.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Health Issues HCR

Public Law 111-148, the Patient Protection and Affordable Care Act - Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and legislative/regulatory issues involved in FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Medicare and Medicaid reimbursement for biotherapeutics, payments under the 340B program, fees on pharmaceutical companies, the Medicare prescription drug benefit.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE

Medicare/Medicaid MMM

Public Law 111-148, the Patient Protection and Affordable Care Act - Medicare and Medicaid reimbursement for biotherapeutics.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Executive Office of the President (EOP)

Pharmacy PHA

H.R. 1548, the Pathway for Biosimilars Act, FDA approval of follow-on biologics. H.R. 1427 and S. 726, the Promoting Innovation and Access to Life-Saving Medicine Act, FDA approval of follow-on biologics. Public Law 111-148, the Patient Protection and Affordable Care Act - FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, design and structure of the Medicare prescription drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Medicare and Medicaid reimbursement issues, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit. S. 1232, the Pharmaceutical Market Access and Drug Safety Act, importation of prescription drugs.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1548 (111th), S. 726 (111th), H.R. 1427 (111th), S. 1232 (111th)

Medical/Disease Research/Clinical Labs MED

Public Law 111-148, the Patient Protection and Affordable Care Act of 2009 - authorization for comparative effectiveness research. S. 1213, the Patient-Centered Outcomes Research Act of 2009 - authorization for comparative effectiveness research.

LobbyistCovered position, as disclosed
RICHARD JOSEPH TARPLIN and Families

Contacted: Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1213 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.